Abbott – Operating Expenses

Quarterly charts & data from official filings

Timeframe

Operating expenses

Operating expensesTable view

Earnings release date
Cost of products sold
Amortization of intangible assets
Research and development
Selling, general and administrative
Total
Earnings release date:16 Jul. 26
Cost of products sold:
5,325,000,000 $+8.9%
Amortization of intangible assets:
658,000,000 $+55.9%
Research and development:
892,000,000 $+16.3%
Selling, general and administrative:
4,025,000,000 $+7.6%
Total:
10,900,000,000 $+11.0%
Earnings release date:16 Apr. 26
Cost of products sold:
4,890,000,000 $-0.7%
Amortization of intangible assets:
422,000,000 $+0.0%
Research and development:
767,000,000 $+4.4%
Selling, general and administrative:
3,740,000,000 $+19.5%
Total:
9,819,000,000 $+6.6%
Earnings release date:22 Jan. 26
Cost of products sold:
4,922,000,000 $-3.0%
Amortization of intangible assets:
422,000,000 $+0.5%
Research and development:
735,000,000 $-4.0%
Selling, general and administrative:
3,129,000,000 $+2.6%
Total:
9,208,000,000 $-1.1%
Earnings release date:15 Oct. 25
Cost of products sold:
5,075,000,000 $+4.6%
Amortization of intangible assets:
420,000,000 $+0.0%
Research and development:
766,000,000 $+5.7%
Selling, general and administrative:
3,051,000,000 $-1.3%
Total:
9,312,000,000 $+2.4%
Earnings release date:17 Jul. 25
Cost of products sold:
4,854,000,000 $+8.6%
Amortization of intangible assets:
420,000,000 $+0.0%
Research and development:
725,000,000 $+1.3%
Selling, general and administrative:
3,091,000,000 $+1.0%
Total:
9,090,000,000 $+4.9%
Earnings release date:16 Apr. 25
Cost of products sold:
4,468,000,000 $-9.6%
Amortization of intangible assets:
420,000,000 $-9.7%
Research and development:
716,000,000 $-4.4%
Selling, general and administrative:
3,061,000,000 $+5.3%
Total:
8,665,000,000 $-4.4%
Earnings release date:22 Jan. 25
Cost of products sold:
4,942,000,000 $+5.2%
Amortization of intangible assets:
465,000,000 $-1.1%
Research and development:
749,000,000 $+5.0%
Selling, general and administrative:
2,907,000,000 $+0.4%
Total:
9,063,000,000 $+3.3%
Earnings release date:16 Oct. 24
Cost of products sold:
4,698,000,000 $+2.1%
Amortization of intangible assets:
470,000,000 $-0.2%
Research and development:
713,000,000 $+2.1%
Selling, general and administrative:
2,895,000,000 $-1.4%
Total:
8,776,000,000 $+0.8%
Earnings release date:18 Jul. 24
Cost of products sold:
4,603,000,000 $+3.1%
Amortization of intangible assets:
471,000,000 $-0.2%
Research and development:
698,000,000 $+2.0%
Selling, general and administrative:
2,936,000,000 $-0.8%
Total:
8,708,000,000 $+1.5%
Earnings release date:17 Apr. 24
Cost of products sold:
4,463,000,000 $-2.0%
Amortization of intangible assets:
472,000,000 $-1.9%
Research and development:
684,000,000 $-2.3%
Selling, general and administrative:
2,959,000,000 $+8.6%
Total:
8,578,000,000 $+1.4%
Earnings release date:24 Jan. 24
Cost of products sold:
4,556,000,000 $-1.1%
Amortization of intangible assets:
481,000,000 $-3.0%
Research and development:
700,000,000 $+4.2%
Selling, general and administrative:
2,724,000,000 $+0.0%
Total:
8,461,000,000 $-0.4%
Earnings release date:18 Oct. 23
Cost of products sold:
4,605,000,000 $+2.7%
Amortization of intangible assets:
496,000,000 $-0.4%
Research and development:
672,000,000 $-6.0%
Selling, general and administrative:
2,723,000,000 $-0.6%
Total:
8,496,000,000 $+0.7%
Earnings release date:20 Jul. 23
Cost of products sold:
4,483,000,000 $+3.5%
Amortization of intangible assets:
498,000,000 $+1.4%
Research and development:
715,000,000 $+9.3%
Selling, general and administrative:
2,740,000,000 $-0.8%
Total:
8,436,000,000 $+2.4%
Earnings release date:19 Apr. 23
Cost of products sold:
4,331,000,000 $-5.7%
Amortization of intangible assets:
491,000,000 $-1.0%
Research and development:
654,000,000 $-9.8%
Selling, general and administrative:
2,762,000,000 $-7.1%
Total:
8,238,000,000 $-6.2%
Earnings release date:25 Jan. 23
Cost of products sold:
4,593,000,000 $-0.8%
Amortization of intangible assets:
496,000,000 $-0.4%
Research and development:
725,000,000 $-7.3%
Selling, general and administrative:
2,973,000,000 $+8.9%
Total:
8,787,000,000 $+1.7%
Earnings release date:19 Oct. 22
Cost of products sold:
4,629,000,000 $-6.2%
Amortization of intangible assets:
498,000,000 $-1.8%
Research and development:
782,000,000 $+14.3%
Selling, general and administrative:
2,731,000,000 $-0.9%
Total:
8,640,000,000 $-2.7%
Earnings release date:20 Jul. 22
Cost of products sold:
4,933,000,000 $
Amortization of intangible assets:
507,000,000 $
Research and development:
684,000,000 $
Selling, general and administrative:
2,757,000,000 $
Total:
8,881,000,000 $

Revenue by segment

Revenue by segmentTable view

Earnings release date
Nutrition
Diagnostics
Established Pharmaceuticals
Medical Devices
Other
Total
Earnings release date:16 Jul. 26
Nutrition:
2,144,000,000 $+6.3%
Diagnostics:
3,092,000,000 $+41.8%
Established Pharmaceuticals:
1,499,000,000 $+5.1%
Medical Devices:
5,853,000,000 $+5.7%
Other:
5,000,000 $+150.0%
Total:
12,593,000,000 $+12.8%
Earnings release date:16 Apr. 26
Nutrition:
2,017,000,000 $+4.0%
Diagnostics:
2,180,000,000 $-11.3%
Established Pharmaceuticals:
1,426,000,000 $+3.2%
Medical Devices:
5,539,000,000 $-2.4%
Other:
2,000,000 $-60.0%
Total:
11,164,000,000 $-2.6%
Earnings release date:22 Jan. 26
Nutrition:
1,940,000,000 $-9.9%
Diagnostics:
2,457,000,000 $+9.1%
Established Pharmaceuticals:
1,382,000,000 $-8.5%
Medical Devices:
5,675,000,000 $+4.2%
Other:
5,000,000 $+25.0%
Total:
11,459,000,000 $+0.8%
Earnings release date:15 Oct. 25
Nutrition:
2,153,000,000 $-2.7%
Diagnostics:
2,253,000,000 $+3.7%
Established Pharmaceuticals:
1,511,000,000 $+9.3%
Medical Devices:
5,448,000,000 $+1.5%
Other:
4,000,000 $-20.0%
Total:
11,369,000,000 $+2.0%
Earnings release date:17 Jul. 25
Nutrition:
2,212,000,000 $+3.1%
Diagnostics:
2,173,000,000 $+5.8%
Established Pharmaceuticals:
1,383,000,000 $+9.8%
Medical Devices:
5,369,000,000 $+9.7%
Other:
5,000,000 $+66.7%
Total:
11,142,000,000 $+7.6%
Earnings release date:16 Apr. 25
Nutrition:
2,146,000,000 $+0.8%
Diagnostics:
2,054,000,000 $-18.5%
Established Pharmaceuticals:
1,260,000,000 $-0.6%
Medical Devices:
4,895,000,000 $-3.1%
Other:
3,000,000 $-40.0%
Total:
10,358,000,000 $-5.6%
Earnings release date:22 Jan. 25
Nutrition:
2,129,000,000 $+3.0%
Diagnostics:
2,520,000,000 $+4.5%
Established Pharmaceuticals:
1,268,000,000 $-9.8%
Medical Devices:
5,052,000,000 $+6.4%
Other:
5,000,000 $+25.0%
Total:
10,974,000,000 $+3.2%
Earnings release date:16 Oct. 24
Nutrition:
2,066,000,000 $-3.9%
Diagnostics:
2,412,000,000 $+9.9%
Established Pharmaceuticals:
1,406,000,000 $+8.7%
Medical Devices:
4,747,000,000 $+0.3%
Other:
4,000,000 $+0.0%
Total:
10,635,000,000 $+2.5%
Earnings release date:18 Jul. 24
Nutrition:
2,150,000,000 $+4.0%
Diagnostics:
2,195,000,000 $-0.9%
Established Pharmaceuticals:
1,294,000,000 $+5.5%
Medical Devices:
4,734,000,000 $+6.3%
Other:
4,000,000 $+33.3%
Total:
10,377,000,000 $+4.1%
Earnings release date:17 Apr. 24
Nutrition:
2,068,000,000 $+1.5%
Diagnostics:
2,214,000,000 $-12.6%
Established Pharmaceuticals:
1,226,000,000 $+0.3%
Medical Devices:
4,453,000,000 $+0.2%
Other:
3,000,000 $-25.0%
Total:
9,964,000,000 $-2.7%
Earnings release date:24 Jan. 24
Nutrition:
2,038,000,000 $-1.7%
Diagnostics:
2,534,000,000 $+3.5%
Established Pharmaceuticals:
1,222,000,000 $-10.7%
Medical Devices:
4,443,000,000 $+4.6%
Other:
4,000,000 $+0.0%
Total:
10,241,000,000 $+1.0%
Earnings release date:18 Oct. 23
Nutrition:
2,073,000,000 $-0.1%
Diagnostics:
2,449,000,000 $+5.7%
Established Pharmaceuticals:
1,368,000,000 $+6.3%
Medical Devices:
4,249,000,000 $-1.1%
Other:
4,000,000 $+33.3%
Total:
10,143,000,000 $+1.7%
Earnings release date:20 Jul. 23
Nutrition:
2,076,000,000 $+5.5%
Diagnostics:
2,317,000,000 $-13.8%
Established Pharmaceuticals:
1,287,000,000 $+8.2%
Medical Devices:
4,295,000,000 $+10.1%
Other:
3,000,000 $+0.0%
Total:
9,978,000,000 $+2.4%
Earnings release date:19 Apr. 23
Nutrition:
1,967,000,000 $+8.3%
Diagnostics:
2,688,000,000 $-18.7%
Established Pharmaceuticals:
1,189,000,000 $-2.2%
Medical Devices:
3,900,000,000 $+4.0%
Other:
3,000,000 $+0.0%
Total:
9,747,000,000 $-3.4%
Earnings release date:25 Jan. 23
Nutrition:
1,817,000,000 $+1.2%
Diagnostics:
3,305,000,000 $-10.0%
Established Pharmaceuticals:
1,216,000,000 $-8.3%
Medical Devices:
3,750,000,000 $+3.7%
Other:
3,000,000 $+0.0%
Total:
10,091,000,000 $-3.1%
Earnings release date:19 Oct. 22
Nutrition:
1,795,000,000 $-8.1%
Diagnostics:
3,671,000,000 $-15.1%
Established Pharmaceuticals:
1,326,000,000 $+8.4%
Medical Devices:
3,615,000,000 $-3.8%
Other:
3,000,000 $+50.0%
Total:
10,410,000,000 $-7.5%
Earnings release date:20 Jul. 22
Nutrition:
1,953,000,000 $
Diagnostics:
4,322,000,000 $
Established Pharmaceuticals:
1,223,000,000 $
Medical Devices:
3,757,000,000 $
Other:
2,000,000 $
Total:
11,257,000,000 $

Revenue by geographic location

Revenue by geographic locationTable view

Earnings release date
United States
International
Total
Earnings release date:16 Jul. 26
United States:
5,216,000,000 $+22.0%
International:
7,377,000,000 $+7.1%
Total:
12,593,000,000 $+12.8%
Earnings release date:16 Apr. 26
United States:
4,274,000,000 $-2.5%
International:
6,890,000,000 $-2.6%
Total:
11,164,000,000 $-2.6%
Earnings release date:22 Jan. 26
United States:
4,383,000,000 $+2.0%
International:
7,076,000,000 $+0.1%
Total:
11,459,000,000 $+0.8%
Earnings release date:15 Oct. 25
United States:
4,299,000,000 $+0.5%
International:
7,070,000,000 $+3.0%
Total:
11,369,000,000 $+2.0%
Earnings release date:17 Jul. 25
United States:
4,276,000,000 $+2.6%
International:
6,866,000,000 $+10.9%
Total:
11,142,000,000 $+7.6%
Earnings release date:16 Apr. 25
United States:
4,168,000,000 $-4.0%
International:
6,190,000,000 $-6.7%
Total:
10,358,000,000 $-5.6%
Earnings release date:22 Jan. 25
United States:
4,341,000,000 $+3.3%
International:
6,633,000,000 $+3.1%
Total:
10,974,000,000 $+3.2%
Earnings release date:16 Oct. 24
United States:
4,202,000,000 $+6.8%
International:
6,433,000,000 $-0.2%
Total:
10,635,000,000 $+2.5%
Earnings release date:18 Jul. 24
United States:
3,934,000,000 $+2.3%
International:
6,443,000,000 $+5.3%
Total:
10,377,000,000 $+4.1%
Earnings release date:17 Apr. 24
United States:
3,846,000,000 $-2.6%
International:
6,118,000,000 $-2.8%
Total:
9,964,000,000 $-2.7%
Earnings release date:24 Jan. 24
United States:
3,949,000,000 $+3.5%
International:
6,292,000,000 $-0.5%
Total:
10,241,000,000 $+1.0%
Earnings release date:18 Oct. 23
United States:
3,817,000,000 $+1.6%
International:
6,326,000,000 $+1.7%
Total:
10,143,000,000 $+1.7%
Earnings release date:20 Jul. 23
United States:
3,758,000,000 $-4.3%
International:
6,220,000,000 $+6.9%
Total:
9,978,000,000 $+2.4%
Earnings release date:19 Apr. 23
United States:
3,928,000,000 $-6.9%
International:
5,819,000,000 $-0.9%
Total:
9,747,000,000 $-3.4%
Earnings release date:25 Jan. 23
United States:
4,219,000,000 $+3.1%
International:
5,872,000,000 $-7.0%
Total:
10,091,000,000 $-3.1%
Earnings release date:19 Oct. 22
United States:
4,094,000,000 $-16.3%
International:
6,316,000,000 $-0.8%
Total:
10,410,000,000 $-7.5%
Earnings release date:20 Jul. 22
United States:
4,892,000,000 $
International:
6,365,000,000 $
Total:
11,257,000,000 $

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:16 Jul. 26
Net income (shareholders):
928,000,000 $-13.8%
Free cash flow:
2,084,000,000 $+127.5%
Total:
3,012,000,000 $+51.1%
Earnings release date:16 Apr. 26
Net income (shareholders):
1,077,000,000 $-51.2%
Free cash flow:
916,000,000 $-58.0%
Total:
1,993,000,000 $-54.6%
Earnings release date:22 Jan. 26
Net income (shareholders):
2,206,000,000 $+34.2%
Free cash flow:
2,182,000,000 $-54.2%
Total:
4,388,000,000 $-31.6%
Earnings release date:15 Oct. 25
Net income (shareholders):
1,644,000,000 $+262.1%
Free cash flow:
4,769,000,000 $+195.8%
Total:
6,413,000,000 $+210.4%
Earnings release date:17 Jul. 25
Net income (shareholders):
454,000,000 $-65.7%
Free cash flow:
1,612,000,000 $+72.8%
Total:
2,066,000,000 $-8.5%
Earnings release date:16 Apr. 25
Net income (shareholders):
1,325,000,000 $-85.6%
Free cash flow:
933,000,000 $-68.5%
Total:
2,258,000,000 $-81.5%
Earnings release date:22 Jan. 25
Net income (shareholders):
9,229,000,000 $+460.7%
Free cash flow:
2,958,000,000 $-14.9%
Total:
12,187,000,000 $+137.9%
Earnings release date:16 Oct. 24
Net income (shareholders):
1,646,000,000 $+26.4%
Free cash flow:
3,477,000,000 $+81.5%
Total:
5,123,000,000 $+59.2%
Earnings release date:18 Jul. 24
Net income (shareholders):
1,302,000,000 $+6.3%
Free cash flow:
1,916,000,000 $+205.6%
Total:
3,218,000,000 $+73.8%
Earnings release date:17 Apr. 24
Net income (shareholders):
1,225,000,000 $-43.5%
Free cash flow:
627,000,000 $-66.0%
Total:
1,852,000,000 $-53.8%
Earnings release date:24 Jan. 24
Net income (shareholders):
2,168,000,000 $+51.0%
Free cash flow:
1,844,000,000 $+55.2%
Total:
4,012,000,000 $+52.9%
Earnings release date:18 Oct. 23
Net income (shareholders):
1,436,000,000 $+2419.3%
Free cash flow:
1,188,000,000 $+158.8%
Total:
2,624,000,000 $+408.5%
Earnings release date:20 Jul. 23
Net income (shareholders):
57,000,000 $-95.7%
Free cash flow:
459,000,000 $-39.8%
Total:
516,000,000 $-75.2%
Earnings release date:19 Apr. 23
Net income (shareholders):
1,318,000,000 $+27.6%
Free cash flow:
763,000,000 $+155.3%
Total:
2,081,000,000 $+56.2%
Earnings release date:25 Jan. 23
Net income (shareholders):
1,033,000,000 $-28.0%
Free cash flow:
298,900,000 $-91.3%
Total:
1,331,900,000 $-72.6%
Earnings release date:19 Oct. 22
Net income (shareholders):
1,435,000,000 $-28.9%
Free cash flow:
3,420,000,000 $+40.9%
Total:
4,855,000,000 $+9.2%
Earnings release date:20 Jul. 22
Net income (shareholders):
2,018,000,000 $
Free cash flow:
2,428,000,000 $
Total:
4,446,000,000 $

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:16 Jul. 26
Profit margin (shareholders):
7.37 %-2.3 pp
Profit margin (free cash flow):
16.55 %+8.3 pp
Earnings release date:16 Apr. 26
Profit margin (shareholders):
9.65 %-9.6 pp
Profit margin (free cash flow):
8.2 %-10.8 pp
Earnings release date:22 Jan. 26
Profit margin (shareholders):
19.25 %+4.8 pp
Profit margin (free cash flow):
19.04 %-22.9 pp
Earnings release date:15 Oct. 25
Profit margin (shareholders):
14.46 %+10.4 pp
Profit margin (free cash flow):
41.95 %+27.5 pp
Earnings release date:17 Jul. 25
Profit margin (shareholders):
4.07 %-8.7 pp
Profit margin (free cash flow):
14.47 %+5.5 pp
Earnings release date:16 Apr. 25
Profit margin (shareholders):
12.79 %-71.3 pp
Profit margin (free cash flow):
9.01 %-17.9 pp
Earnings release date:22 Jan. 25
Profit margin (shareholders):
84.1 %+68.6 pp
Profit margin (free cash flow):
26.95 %-5.7 pp
Earnings release date:16 Oct. 24
Profit margin (shareholders):
15.48 %+2.9 pp
Profit margin (free cash flow):
32.69 %+14.2 pp
Earnings release date:18 Jul. 24
Profit margin (shareholders):
12.55 %+0.3 pp
Profit margin (free cash flow):
18.46 %+12.2 pp
Earnings release date:17 Apr. 24
Profit margin (shareholders):
12.29 %-8.9 pp
Profit margin (free cash flow):
6.29 %-11.7 pp
Earnings release date:24 Jan. 24
Profit margin (shareholders):
21.17 %+7.0 pp
Profit margin (free cash flow):
18.01 %+6.3 pp
Earnings release date:18 Oct. 23
Profit margin (shareholders):
14.16 %+13.6 pp
Profit margin (free cash flow):
11.71 %+7.1 pp
Earnings release date:20 Jul. 23
Profit margin (shareholders):
0.57 %-13.0 pp
Profit margin (free cash flow):
4.6 %-3.2 pp
Earnings release date:19 Apr. 23
Profit margin (shareholders):
13.52 %+3.3 pp
Profit margin (free cash flow):
7.83 %+4.9 pp
Earnings release date:25 Jan. 23
Profit margin (shareholders):
10.24 %-3.5 pp
Profit margin (free cash flow):
2.96 %-29.9 pp
Earnings release date:19 Oct. 22
Profit margin (shareholders):
13.78 %-4.1 pp
Profit margin (free cash flow):
32.85 %+11.3 pp
Earnings release date:20 Jul. 22
Profit margin (shareholders):
17.93 %
Profit margin (free cash flow):
21.57 %

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:16 Jul. 26
Capital expenditure:
497,000,000 $+24.6%
Earnings release date:16 Apr. 26
Capital expenditure:
399,000,000 $-39.4%
Earnings release date:22 Jan. 26
Capital expenditure:
658,000,000 $-55.6%
Earnings release date:15 Oct. 25
Capital expenditure:
1,482,000,000 $+195.2%
Earnings release date:17 Jul. 25
Capital expenditure:
502,000,000 $+3.7%
Earnings release date:16 Apr. 25
Capital expenditure:
484,000,000 $-14.9%
Earnings release date:22 Jan. 25
Capital expenditure:
569,000,000 $+1.4%
Earnings release date:16 Oct. 24
Capital expenditure:
561,000,000 $+5.3%
Earnings release date:18 Jul. 24
Capital expenditure:
533,000,000 $+33.9%
Earnings release date:17 Apr. 24
Capital expenditure:
398,000,000 $-31.0%
Earnings release date:24 Jan. 24
Capital expenditure:
577,000,000 $-11.6%
Earnings release date:18 Oct. 23
Capital expenditure:
653,000,000 $+34.1%
Earnings release date:20 Jul. 23
Capital expenditure:
487,000,000 $+28.2%
Earnings release date:19 Apr. 23
Capital expenditure:
380,000,000 $-14.2%
Earnings release date:25 Jan. 23
Capital expenditure:
443,000,000 $+7.3%
Earnings release date:19 Oct. 22
Capital expenditure:
413,000,000 $+6.2%
Earnings release date:20 Jul. 22
Capital expenditure:
389,000,000 $